{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Coagulopathies&page=3",
    "query": {
      "condition": "Coagulopathies",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 891,
    "total_pages": 90,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Coagulopathies&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Coagulopathies&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T09:33:50.725Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05387577",
      "title": "Coagulation and Fibrinolysis of Estradiol in Transwomen",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Transgenderism",
        "Clotting Disorder"
      ],
      "interventions": [
        {
          "name": "Estradiol Tablets",
          "type": "DRUG"
        },
        {
          "name": "Transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2021-12-07",
      "completion_date": "2022-11-23",
      "has_results": false,
      "last_update_posted_date": "2022-12-21",
      "last_synced_at": "2026-10-02T09:33:50.725Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05387577"
    },
    {
      "nct_id": "NCT00076557",
      "title": "Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Adeno-Associated Viral with Human Factor IX",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Avigen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2004-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-04-04",
      "last_synced_at": "2026-10-02T09:33:50.725Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076557"
    },
    {
      "nct_id": "NCT00001456",
      "title": "Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hermansky-Pudlak Syndrome (HPS)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "115 Years",
        "sex": "ALL",
        "summary": "1 Month to 115 Years"
      },
      "enrollment_count": 600,
      "start_date": "1995-11-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-02T09:33:50.725Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001456"
    },
    {
      "nct_id": "NCT02283268",
      "title": "Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Disease"
      ],
      "interventions": [
        {
          "name": "Recombinant von Willebrand Factor (rVWF)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2015-04-01",
      "completion_date": "2016-07-06",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-10-02T09:33:50.725Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • Miami, Florida • Augusta, Georgia + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02283268"
    },
    {
      "nct_id": "NCT03275740",
      "title": "A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Primary Immune Thrombocytopenia",
        "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"
      ],
      "interventions": [
        {
          "name": "PF-06755347 intravenous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "Placebo intravenous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "PF-06755347 subcutaneous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "Placebo subcutaneous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "PF-06755347 subcutaneous ITP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 58,
      "start_date": "2017-07-17",
      "completion_date": "2023-01-06",
      "has_results": true,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-10-02T09:33:50.725Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03275740"
    },
    {
      "nct_id": "NCT06721013",
      "title": "A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia (ITP)"
      ],
      "interventions": [
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2025-07-30",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-02T09:33:50.725Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06721013"
    },
    {
      "nct_id": "NCT01962415",
      "title": "Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency (PID)",
        "Congenital Bone Marrow Failure Syndromes",
        "Inherited Metabolic Disorders (IMD)",
        "Hereditary Anemias",
        "Inflammatory Conditions",
        "Systemic Juvenile Idiopathic Arthritis (sJIA)",
        "Juvenile Rheumatoid Arthritis (JRA)"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "2 Months to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-02-04",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-10-02T09:33:50.725Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962415"
    },
    {
      "nct_id": "NCT02273960",
      "title": "Study to Evaluate Safety and Efficacy in Adult Subjects With ITP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "BMS-986004 75 mg IV",
          "type": "DRUG"
        },
        {
          "name": "BMS-986004 225 mg IV",
          "type": "DRUG"
        },
        {
          "name": "BMS-986004 675 mg IV",
          "type": "DRUG"
        },
        {
          "name": "BMS-986004 1500 mg IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2014-11-17",
      "completion_date": "2018-01-22",
      "has_results": true,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-10-02T09:33:50.725Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02273960"
    },
    {
      "nct_id": "NCT01440946",
      "title": "Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "rFIXFc",
          "type": "DRUG"
        },
        {
          "name": "FIX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioverativ Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "11 Years",
        "sex": "MALE",
        "summary": "Up to 11 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2012-06",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-10-02T09:33:50.725Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01440946"
    },
    {
      "nct_id": "NCT03248141",
      "title": "Understanding Hemophilia A and B Drug Dosage Administration Patterns",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Hemophilia B standard half-life",
          "type": "DRUG"
        },
        {
          "name": "Hemophilia B extended half-life",
          "type": "DRUG"
        },
        {
          "name": "Hemophilia A standard half-life",
          "type": "DRUG"
        },
        {
          "name": "Hemophilia A extended half-life",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 11,
      "start_date": "2017-09-01",
      "completion_date": "2018-03-14",
      "has_results": true,
      "last_update_posted_date": "2019-05-20",
      "last_synced_at": "2026-10-02T09:33:50.725Z",
      "location_count": 3,
      "location_summary": "Gainesville, Florida • Las Vegas, Nevada • Fort Worth, Texas",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03248141"
    }
  ]
}